201 related articles for article (PubMed ID: 27990784)
21. Immune tolerance induction: What have we learned over time?
Brackmann HH; White GC; Berntorp E; Andersen T; Escuriola-Ettingshausen C
Haemophilia; 2018 Apr; 24 Suppl 3():3-14. PubMed ID: 29543371
[TBL] [Abstract][Full Text] [Related]
22. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
24. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
[TBL] [Abstract][Full Text] [Related]
25. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
Benson G; Auerswald G; Elezović I; Lambert T; Ljung R; Morfini M; Remor E; Salek SZ
Eur J Haematol; 2012 May; 88(5):371-9. PubMed ID: 22260405
[TBL] [Abstract][Full Text] [Related]
26. The burden of inhibitors in haemophilia patients.
Walsh CE; Jiménez-Yuste V; Auerswald G; Grancha S
Thromb Haemost; 2016 Aug; 116 Suppl 1():S10-7. PubMed ID: 27528280
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.
Jiménez-Yuste V; Oldenburg J; Rangarajan S; Peiró-Jordán R; Santagostino E
Haemophilia; 2016 Nov; 22(6):859-865. PubMed ID: 27329267
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of inhibitors and current treatment strategies.
Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
[TBL] [Abstract][Full Text] [Related]
29. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
30. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.
Valentino LA; Kempton CL; Kruse-Jarres R; Mathew P; Meeks SL; Reiss UM;
Haemophilia; 2015 Sep; 21(5):559-67. PubMed ID: 26032231
[TBL] [Abstract][Full Text] [Related]
31. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
[TBL] [Abstract][Full Text] [Related]
32. Impact of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: A survey of Haemophilia and Thrombosis Research Society members.
Sande CM; Al-Huniti A; Ten Eyck P; Sharathkumar AA
Haemophilia; 2019 Sep; 25(5):764-772. PubMed ID: 31264762
[TBL] [Abstract][Full Text] [Related]
33. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
34. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
Coppola A; Di Minno MN; Santagostino E
Br J Haematol; 2010 Sep; 150(5):515-28. PubMed ID: 20573153
[TBL] [Abstract][Full Text] [Related]
35. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
36. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
38. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
[TBL] [Abstract][Full Text] [Related]
39. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).
Rocino A; Cortesi PA; Scalone L; Mantovani LG; Crea R; Gringeri A; ;
Haemophilia; 2016 Jan; 22(1):96-102. PubMed ID: 26278414
[TBL] [Abstract][Full Text] [Related]
40. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
